Back to Search
Start Over
AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2004 Oct; Vol. 48 (10), pp. 4050-3. - Publication Year :
- 2004
-
Abstract
- Cloning, sequencing, and biochemical analysis identified a novel AmpC-type beta-lactamase conferring resistance to extended-spectrum cephalosporins in an Escherichia coli clinical isolate. This enzyme, exhibiting 14 amino acid substitutions compared to a reference AmpC cephalosporinase of E. coli, hydrolyzed ceftazidime and cefepime significantly.
- Subjects :
- Aged
Aged, 80 and over
Amino Acid Sequence
Amino Acid Substitution
Bacterial Proteins genetics
Cefepime
Ceftazidime pharmacology
Cephalosporins pharmacology
Cloning, Molecular
DNA, Bacterial genetics
Escherichia coli drug effects
Escherichia coli genetics
Female
Humans
Kinetics
Molecular Sequence Data
beta-Lactamases genetics
Bacterial Proteins metabolism
Cephalosporin Resistance genetics
Escherichia coli enzymology
Escherichia coli Infections microbiology
beta-Lactamases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0066-4804
- Volume :
- 48
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 15388478
- Full Text :
- https://doi.org/10.1128/AAC.48.10.4050-4053.2004